BHC
Bausch Health Companies Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
6.49
▼ 0.32 (4.73%)
MARKET · —
Price
Open
6.81
Prev close
6.81
Day high
6.87
Day low
6.38
Volume
3.97M
Market cap
$2.41B
P/E (TTM)
—
52W range
4.33 – 8.00
Trailing performance
Returnvs SPY
1W
-1.08%
+0.3%
1M
+44.72%
+41.0%
3M
+18.17%
+15.1%
6M
+5.06%
-6.0%
YTD
-7.34%
-19.6%
1Y
-15.04%
-35.0%
3Y
-22.87%
-97.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$2.41B
Enterprise value$22.33B
Revenue (TTM)$10.85B
Gross profit$7.79B
EBITDA$3.91B
Net income$-1.10B
EPS (TTM)$-2.94
Free cash flow$1.43B
Total cash$1.82B
Total debt$20.78B
Book value / share$-4.74
Shares outstanding373.99M
Float260.53M
Short % of float2.53%
Dividend yield—
Beta (5Y)0.38
Valuation & profitability ratios
Trailing P/E—
Forward P/E1.54
PEG ratio0.01
Price / sales—
Price / book—
EV / revenue2.06
EV / EBITDA5.71
Gross margin71.82%
Operating margin27.17%
Profit margin-10.12%
Return on equity—
Return on assets6.57%
Debt / equity—
Current ratio1.44
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $10.27B | $9.63B | $8.76B | $8.12B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $157.00M | -$46.00M | -$592.00M | -$225.00M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $157.00M | -$46.00M | -$592.00M | -$225.00M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.01 | 1.26 | +25.1% |
| Mar 2026 | 0.69 | 0.78 | +12.8% |
| Dec 2025 | 1.26 | 1.10 | -12.9% |
| Sep 2025 | 1.06 | 1.16 | +10.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.19 | 5 | $2.75B | +2.4% |
| Next quarter | 1.27 | 5 | $2.80B | +0.1% |
| Current year | 4.47 | 6 | $10.88B | +6.0% |
| Next year | 4.19 | 6 | $10.89B | +0.0% |
Analyst targets & ownership
Mean target$7.50
High target$9.00
Low target$6.50
Implied upside15.59%
Analyst count5
ConsensusNONE
Strong buy / Buy0 / 0
Hold7
Sell / Strong sell0 / 0
Held by insiders11.12%
Held by institutions65.06%
Institutions holding314
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
41.60M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | LEUNG SANDRA Director |
STOCK | 6.84K | $33.75K | Direct |
| Jun 30, 26 | PAULSON JOHN A. Director |
STOCK | 12.68K | $62.50K | Direct |
| May 22, 26 | POWER ROBERT N Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | LEUNG SANDRA Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | PAULSON JOHN A. Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | KAVANAGH SARAH BALDWIN Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | ROBERTS EIRY WYN Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | GOETTLER MICHAEL Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | LEE FRANK DON Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | GARCIA CHRISTIAN A Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | WECHSLER AMY B Director |
STOCK | 45.87K | $0 | Direct |
| May 19, 26 | LEE FRANK DON Director |
SELL | 24.46K | $132.80K | Direct |
| Mar 31, 26 | LEUNG SANDRA Director |
STOCK | 5.95K | $32.11K | Direct |
| Mar 31, 26 | PAULSON JOHN A. Director |
STOCK | 11.57K | $62.50K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
APPIO THOMAS J |
Chief Executive Officer | 3.62M | Stock Award(Grant) |
CARSON SEANA LYNNE |
General Counsel | 616.76K | Sale |
CHARHON JEAN-JACQUES |
Chief Financial Officer | 755.54K | Stock Award(Grant) |
KAVANAGH SARAH BALDWIN |
Director | 282.23K | Stock Award(Grant) |
LENAR AIMEE J |
Officer | 400.33K | Stock Award(Grant) |
MILLER STEVEN D |
Director | 239.22K | Stock Award(Grant) |
PAULSON & CO., INC. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
PAULSON JOHN A. |
Director | 73.69M | Stock Award(Grant) |
POWER ROBERT N |
Director | 300.59K | Stock Award(Grant) |
WECHSLER AMY B |
Director | 313.58K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
6.53
-0.64% from price
SMA 20
6.19
+4.05% from price
SMA 50
5.37
+19.88% from price
SMA 100
5.43
+19.55% from price
SMA 200
5.86
+9.94% from price
EMA 12
6.45
+0.54% from price
EMA 26
6.04
+7.41% from price
EMA 50
5.71
+13.72% from price
RSI (14)
57.9
Neutral
MACD (12,26,9)
0.41
Hist 0.01
ATR (14)
0.37
5.73% of price
Realised vol 30D
95.2%
Annualised
Bollinger upper
7.68
20, 2σ
Bollinger lower
4.70
20, 2σ
50 / 200 cross
Death
5.37 vs 5.86
Trend bias
Above 200
+9.94%
Risk profile
Beta vs SPY
0.96
Less volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
95.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-43.9%
Peak to trough
Max drawdown 5Y
-85.3%
Peak to trough
ATR 14
0.37
5.73% of price
Beta (reported)
0.38
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
2.04
Put-heavy session
Put / call open interest
0.42
Positioning, not flow
Max pain
1.00
-84.5% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
+5.5%
Puts bid over calls
Call volume
69
Contracts, this expiry
Put volume
141
Contracts, this expiry
Heaviest call OI
1.00
703 contracts
Heaviest put OI
6.00
338 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Can Bausch (BHC) Run Higher on Rising Earnings Estimates?
Zacks · 22h ago
Bausch (BHC) Upgraded to Buy: Here's What You Should Know
Zacks · 22h ago
Bausch Health Companies Insider Sold Shares Worth $258,894, According to a Recent SEC Filing
MT Newswires · 2d ago
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
PR Newswire · 5d ago
Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month
Motley Fool · 12d ago
Bausch Health Chief Executive Thomas Appio Appointed to Bausch + Lomb Board
MT Newswires · 16d ago
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
PR Newswire · 16d ago
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
Business Wire · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.